Zobrazeno 1 - 10
of 210
pro vyhledávání: '"S, Wasser"'
Autor:
June S. Wasser, David J. Greenblatt
Publikováno v:
Journal of Clinical and Translational Science, Vol 7 (2023)
Our drug development process has produced many life-saving medications, but patients experiencing rare diseases and similar conditions often are left with limited options for treatment. For an approved treatment to be developed, research on a new can
Externí odkaz:
https://doaj.org/article/7ec02cc0f7184b38bee61c8c4d034d50
Autor:
Toshihiko Doi, John A Thompson, Omid Hamid, Adi Diab, Siwen Hu-Lieskovan, Jeffrey Chou, Jeffrey S Wasser, Patrick A Ott, Jean-Philippe Spano, Willeke Ros, Alison Forgie, Wenjing Yang, Ferry A L M Eskens, Alberto A Chiappori, Eric Angevin, Naiyer A Rizvi, Cen Guo, Anthony B El-Khoueiry
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Background Ivuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively. This first-in-human, multicenter, open-label, phase I, dose-escalation/dose-expansion study expl
Externí odkaz:
https://doaj.org/article/ccd14bbe12da44b9bec3de265e3da2d8
Autor:
Adam Cuker, Jenny M. Despotovic, Rachael F. Grace, Caroline Kruse, Michele P. Lambert, Howard A. Liebman, Roger M. Lyons, Keith R. McCrae, Vinod Pullarkat, Jeffrey S. Wasser, David Beenhouwer, Sarah N. Gibbs, Irina Yermilov, Michael S. Broder
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 1, Pp 69-80 (2021)
Abstract Background Thrombopoietin receptor agonists (TPO‐RAs) are used to treat primary immune thrombocytopenia (ITP). Some patients have discontinued treatment while maintaining a hemostatic platelet count. Objectives To develop expert consensus
Externí odkaz:
https://doaj.org/article/227a3e2d261045778633731119f64d14
Autor:
Erica L. Carpenter, Roger B. Cohen, Corey J. Langer, Joshua M. Bauml, Jeffrey S. Wasser, Aditi P. Singh, Christine A. Ciunci, Abigail T. Berman, Elena Helman, Rebecca J. Nagy, Kimberly C. Banks, Benjamin A. Silva, Michael J. LaRiviere, Theresa E. Christensen, Stephanie S. Yee, Taylor A. Black, Wei-Ting Hwang, Katie J. Quinn, Austin L. Chien, Jeffrey C. Thompson, Charu Aggarwal
Mutations Analyzed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08350c21e7795ce9c29cff93a63f6bbf
https://doi.org/10.1158/1078-0432.22475610
https://doi.org/10.1158/1078-0432.22475610
Autor:
Erica L. Carpenter, Roger B. Cohen, Corey J. Langer, Joshua M. Bauml, Jeffrey S. Wasser, Aditi P. Singh, Christine A. Ciunci, Abigail T. Berman, Elena Helman, Rebecca J. Nagy, Kimberly C. Banks, Benjamin A. Silva, Michael J. LaRiviere, Theresa E. Christensen, Stephanie S. Yee, Taylor A. Black, Wei-Ting Hwang, Katie J. Quinn, Austin L. Chien, Jeffrey C. Thompson, Charu Aggarwal
Purpose:The role of plasma-based tumor mutation burden (pTMB) in predicting response to pembrolizumab-based first-line standard-of-care therapy for metastatic non–small cell lung cancer (mNSCLC) has not been explored.Experimental Design:A 500-gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dfee398bbbbfc5c85644bb8ae085830
https://doi.org/10.1158/1078-0432.c.6529125
https://doi.org/10.1158/1078-0432.c.6529125
Autor:
Erica L. Carpenter, Roger B. Cohen, Corey J. Langer, Joshua M. Bauml, Jeffrey S. Wasser, Aditi P. Singh, Christine A. Ciunci, Abigail T. Berman, Elena Helman, Rebecca J. Nagy, Kimberly C. Banks, Benjamin A. Silva, Michael J. LaRiviere, Theresa E. Christensen, Stephanie S. Yee, Taylor A. Black, Wei-Ting Hwang, Katie J. Quinn, Austin L. Chien, Jeffrey C. Thompson, Charu Aggarwal
pTMBand PD-L1 expression levels.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::907404d8eb997d205afbd17afc601de9
https://doi.org/10.1158/1078-0432.22475613.v1
https://doi.org/10.1158/1078-0432.22475613.v1
Autor:
Erica L. Carpenter, Roger B. Cohen, Corey J. Langer, Joshua M. Bauml, Jeffrey S. Wasser, Aditi P. Singh, Christine A. Ciunci, Abigail T. Berman, Elena Helman, Rebecca J. Nagy, Kimberly C. Banks, Benjamin A. Silva, Michael J. LaRiviere, Theresa E. Christensen, Stephanie S. Yee, Taylor A. Black, Wei-Ting Hwang, Katie J. Quinn, Austin L. Chien, Jeffrey C. Thompson, Charu Aggarwal
Development and validation of a plasma-based panel for mutation detection and assessment of TMB.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab8830cf164cccd5b1739f881aa15920
https://doi.org/10.1158/1078-0432.22475619.v1
https://doi.org/10.1158/1078-0432.22475619.v1
Autor:
Omid Hamid, Alberto A Chiappori, John A Thompson, Toshihiko Doi, Siwen Hu-Lieskovan, Ferry A L M Eskens, Willeke Ros, Adi Diab, Jean-Philippe Spano, Naiyer A Rizvi, Jeffrey S Wasser, Eric Angevin, Patrick A Ott, Alison Forgie, Wenjing Yang, Cen Guo, Jeffrey Chou, Anthony B El-Khoueiry
Publikováno v:
Journal for ImmunoTherapy of Cancer, 10(10):e005471. BioMed Central Ltd.
BackgroundIvuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively. This first-in-human, multicenter, open-label, phase I, dose-escalation/dose-expansion study explo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa1dda7e7d3a12439bbe12c6f5cc93b2
http://www.scopus.com/inward/record.url?scp=85140857731&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85140857731&partnerID=8YFLogxK
Autor:
Vinod Pullarkat, David O. Beenhouwer, Jeffrey S. Wasser, Jenny M. Despotovic, Keith R. McCrae, Adam Cuker, Michele P. Lambert, Michael S. Broder, Roger M. Lyons, Sarah N Gibbs, Caroline Kruse, Rachael F. Grace, Howard A. Liebman, Irina Yermilov
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 1, Pp 69-80 (2021)
Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis
Background Thrombopoietin receptor agonists (TPO-RAs) are used to treat primary immune thrombocytopenia (ITP). Some patients have discontinued treatment while maintaining a hemostatic platelet count. Objectives To develop expert consensus on when it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d0369238422f3b2bd6937a37aae49a6
https://doaj.org/article/227a3e2d261045778633731119f64d14
https://doaj.org/article/227a3e2d261045778633731119f64d14
Autor:
M Alan Brookhart, Diane Reams, Leah J. McGrath, Ivy Altomare, Anjali Sharma, Robert A. Overman, Karynsa Kilpatrick, Jeffrey S. Wasser
Publikováno v:
Clinical Epidemiology. 12:435-445
Purpose Patients with immune thrombocytopenia (ITP) have low platelet counts and an increased risk of bleeding. We described treatment patterns and clinical outcomes in routine practice in the United States (US). Patients and Methods Using electronic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::335ef3c86e8854348ea566a924a13137
https://doi.org/10.2147/clep.s229266
https://doi.org/10.2147/clep.s229266